"The most effective healthcare relies on the rapid adoption of new technologies and treatments.” You will find these words in the opening statement of the government’s Life Sciences Sector Plan, published a year ago. While it may be too soon to draw conclusions on whether the plan has delivered fully on its ambitions, it is worth considering whether we are starting to see progress towards rapid adoption in one area above all - obesity care. 

Obesity costs the NHS £11.4 billion a year and places a significant additional burden on the wider economy through lost productivity and reduced workforce participation. That broader impact has been estimated by NESTA at 2-3% of GDP. 

New treatments, including GLP-1 medications, have changed what can be achieved for millions of people. But having access to a prescription is not the same as securing lasting health benefits. Obesity is a complex condition shaped by the interplay of clinical, behavioural, social, and environmental factors. If treatment is delivered transactionally, the opportunity it presents to the country will be wasted. If it is delivered through clinically governed, technology-enabled care pathways, it can become a foundational pillar of prevention strategy, improve outcomes and create tremendous value for the NHS. 

Working with East Suffolk and North Essex Foundation Trust, Reset Health has reduced specialist weight management waiting times from two years to eight days. By ensuring patients have personalised dosing support, overall costs for medication have also been reduced by 18%. That is proof that a properly integrated care pathway, built around what patients need to sustain outcomes, can fundamentally change how the system works. And it is proof that it can be delivered in a cost-effective manner while reducing strain on the system.  

The partnership has also achieved lasting outcomes for patients. Usually 30-40% of people cease obesity medication because of side effects, such as nausea, gastrointestinal symptoms, and the difficulty of tolerating dose escalation. By providing clinically governed care, the partnership has helped patients remain on treatment, with over 96% retention at six months. What is more, this was not a carefully selected low-risk group. Average BMI was >47.0, with a mean of seven comorbidities per patient. These were people for whom treatment is complex, and for whom the clinical picture is rarely straightforward. 

The approach aligns closely with the direction set by both the Life Sciences Sector Plan and the 10-Year Health Plan. It supports the prevention agenda, by helping patients manage a chronic condition earlier and more effectively. It provides real value to the NHS by using technology to extend clinical capacity and delivering sustained outcomes. And most importantly, it helps people to live healthier lives.

With treatment expanding rapidly in the private market, responsible growth must be built on clinical standards, safeguarding, monitoring and long-term support. A sustainable market will be built on trust and achieving long term health benefits. 

The Government has invested significantly in GLP-1 medications, and rightly so. One year on from the Life Sciences Sector Plan, there is good reason to welcome the progress made in bringing health improvement, innovation and economic growth into a joined-up national mission. The next phase should focus on turning that ambition into safe, practical delivery at scale. That means the continued adoption of proven innovation, use of real-world evidence and commissioning models that deliver sustained outcomes.